GSK plc American Depositary Shares (Each representing two Ordinary Shares) (GSK)
38.43
+0.48 (1.26%)
GSK Plc is a global healthcare company dedicated to improving the quality of human life by enabling people to do more, feel better, and live longer
The company specializes in the research, development, and manufacturing of a wide range of pharmaceuticals, vaccines, and consumer health products. GSK's portfolio covers various therapeutic areas, including respiratory diseases, HIV, oncology, immunology, and infectious diseases, with a strong emphasis on innovation and scientific advancement. Committed to addressing health challenges, GSK collaborates with various partners and stakeholders to deliver accessible healthcare solutions that meet the needs of patients and communities around the world.
ICER assessed GSK's COPD inhalers, Trelegy Ellipta and Breo Ellipta, for Medicare price negotiations, highlighting their once-daily dosing and comparable net health benefits.
Amgen and AstraZeneca's Tezspire showed significant reductions in nasal polyp severity, congestion, and surgery need in CRSwNP patients in the Phase 3 WAYPOINT trial.
Haleon posted £11.23B in FY24 revenue, with 5% organic growth. 2025 guidance expects 4-6% organic growth, with profit gains weighted to the second half.
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against GSK plc (“GSK” or “the Company”) (NYSEGSK) and certain of its officers.
GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved PENMENVY (Meningococcal Groups A, B, C, W, and Y Vaccine) for use in individuals aged 10 through 25 years. The vaccine targets five major serogroups of Neisseria meningitidis (A, B, C, W, and Y) which commonly cause invasive meningococcal disease (IMD).1,2
Glancy Prongay & Murray LLP reminds investors of the upcoming April 7, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired GSK plc. (“GSK” or the “Company”) (NYSEGSK) American Depositary Receipts (“ADRs”) between February 5, 2020, and August 14, 2022, inclusive (the “Class Period”).
Goldman Sachs downgraded Dynavax to Sell, citing increased competition in the shingles vaccine market and uncertainty over hepatitis B revaccination demand.
Law Offices of Howard G. Smith reminds investors of the upcoming April 7, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased GSK plc. (“GSK” or the “Company”) (NYSEGSK) American Depositary Receipts (“ADRs”) between February 5, 2020, and August 14, 2022, inclusive (the “Class Period”).
The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of investors who purchased GSK plc. (“GSK” or the “Company”) (NYSEGSK) American Depositary Receipts (“ADRs”) between February 5, 2020, and August 14, 2022, inclusive (the “Class Period”). GSK investors have until April 7, 2025 to file a lead plaintiff motion.
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired GSK plc. (“GSK” or the “Company”) (NYSEGSK) American Depositary Receipts (“ADRs”) between February 5, 2020, and August 14, 2022, inclusive (the “Class Period”). GSK investors have until April 7, 2025 to file a lead plaintiff motion.
Merck & Co. stock was pummeled by 10% after its earnings release on soft forecasts, but the overreaction by the market may present a buying opportunity.
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against GSK plc (“GSK” or “the Company”) (NYSEGSK) and certain of its officers.
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased GSK plc. (“GSK” or the “Company”) (NYSEGSK) American Depositary Receipts (“ADRs”) between February 5, 2020, and August 14, 2022, inclusive (the “Class Period”). GSK investors have until April 7, 2025 to file a lead plaintiff motion.
SAN DIEGO, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all purchasers of the American Depository Receipts ("ADRs") of GSK PLC (NYSEGSK) between February 5, 2020 and August 14, 2022. GSK is a global pharmaceutical company that develops, manufactures, and markets vaccines and medicines worldwide.
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against GSK plc (“GSK” or “the Company”) (NYSEGSK) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
